CHICAGO – Is precision medicine (PM) finally within sight? The long-heralded but largely overhyped model got a shot in the arm at the American Society of Clinical Oncology (ASCO) annual meeting in a retrospective analysis of consecutive, prospectively molecularly profiled patients with advanced cancer who participated in a large personalized medicine trial. Investigators found that using molecular tests of tumors to select targeted therapy resulted in slower cancer growth and prolonged survival across a diverse set of cancer types.